SUBTYPING SOCIAL ANXIETY DISORDER IN DEVELOPED AND DEVELOPING COUNTRIES

SAD and numerous outcomes (age-of-onset, persistence, severity, comorbidity, treatment) were examined. Additional analyses examined associations with number of performance fears Versus number of interactional fears. Results: Lifetime social fears are quite common in both developed (15.9%) and developing (14.3%) countries, but lifetime SAD is much more common in the former (6.1%) than latter (2.1%) countries. Among those with SAD, persistence, severity, comorbidity, and treatment have dose response relationships with number of social fears, with no clear nonlinearity in relationships that would support a distinction between generalized and non-generalized SAD. The distinction between performance fears and interactional fears is generally not important in predicting these same outcomes. Conclusion: No evidence is found to support subtyping SAD on the basis of either number of social fears or number of performance fears versus number of interactional fears. Depression and Anxiety 27:390-403, 2010. (C) 2009 Wiley-Liss, Inc.

Japan Ministry of Health. Labour and Welfare[H14 - TOKUBETSU -026]

Japan Ministry of Health. Labour and Welfare[H16-KOKOR0-013]

Lebanese Ministry of Public Health

WHO (Lebanon)

Fogarty International (FIRCA/NIH)

Act for Lebanon

Janssen Cilag

Eli Lilly

GlaxoSmithKline

Roche: Novartis

National Institute of Psychiatry Ramon de la Fuente[4280]

National Council on Science and Technology[CONACyT-G30544-H]

New Zealand Ministry of Health

Alcohol Advisory Council

Health Research Council

WHO (Geneva)

WHO (Nigeria)

Federal Ministry of Health, Abuja, Nigeria

Ministry of Public Health (former Ministry of Health)

US National Institute of Mental Health (NIMH/NIH)[R01-MH059575]

National Institute of Drug

South African Department of Health